Literaturverzeichnis

1. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive care unit admission with sepsis. Crit Care Med. 1995, 23(6): 1040-7.

2. Gopal I, Bhonagiri S, Ronco C, Bellomo R. Out of hospital outcome and quality of life in survivors of combined acute multiple organ and renal failure treated with continuous venovenous hemofiltration/hemodiafiltration. Intensive Care Med. 1997, 23: 766-72

3. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med. 2002, 28(10): 1440-6

4. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995, 27; 274(12): 968-74

5. Glauser, M.P., Zanetti, G. and Cohen, J. Septic shock: pathogenesis. Lancet. 1991, 338: 732-6

6. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med. 1998, 26(12): 2078-86

7. Bone, R.C. Why the sepsis trials failed. JAMA. 1996, 276: 565-6

8. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32(3): 858-73

9. Patel GP, Gurka DP, Balk RA. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care. 2003, 9(5): 390-6

10. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345(19): 1368-77

11. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997, 112(1): 235-43

12. Kline JA, Gordon BE, Williams C, Blumenthal S, Watts JA, Diaz-Buxo J. Large-pore hemodialysis in acute endotoxin shock. Crit Care Med. 1999, 27(3): 588-96

13. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991, 88(5): 1747-54

14. Kikeri D, Pennell JP, Hwang KH, Jacob AI, Richman AV, Bourgoignie JJ. Endotoxemic acute renal failure in awake rats. Am J Physiol. 1986, 250(6 Pt 2): F1098-106

15. Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest. 1990, 98(1): 170-9

16. Ravikant T, Lucas CE. Renal blood flow distribution in septic hyperdynamic pigs. J Surg Res. 1977, 22(3): 294-8

17. Di Giantomasso D, Morimatsu H, May CN, Bellomo R. Intrarenal blood flow distribution in hyperdynamic septic shock: Effect of norepinephrine. Crit Care Med. 2003, 31(10): 2509-13

18. Badr KF, Kelley VE, Rennke HG, Brenner BM. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int. 1986, 30(4): 474-80

19. Churchill PC, Bidani AK, Schwartz MM. Renal effects of endotoxin in the male rat. Am J Physiol. 1987, 253(2 Pt 2): F244-50

20. Wang J, Dunn MJ. Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats. Am J Physiol. 1987, 253(6 Pt 2): F1283-9

21. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeau E, Etienne J, Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int. 1989, 35(5): 1111-8

22. Zurovsky Y, Gispaan I. Antioxidants attenuate endotoxin-induced acute renal failure in rats. Am J Kidney Dis. 1995, 25(1): 51-7

23. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW. Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int. 2001, 59(6): 2243-9

24. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002, 168(11): 5817-23

25. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens. 2002, 11(3): 301-8

26. Sano K, Fujigaki Y, Miyaji T, Ikegaya N, Ohishi K, Yonemura K, Hishida A. Role of apoptosis in uranyl acetate-induced acute renal failure and acquired resistance to uranyl acetate. Kidney Int. 2000, 57(4): 1560-70

27. Meldrum KK, Meldrum DR, Hile KL, Yerkes EB, Ayala A, Cain MP, Rink RC, Casale AJ, Kaefer MA. p38 MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. Am J Physiol Cell Physiol. 2001, 281(2): C563-70

28. Opatrny K Jr. Clinical importance of biocompatibility and its effect on haemodialysis treatment. Nephrol Dial Transplant. 2003, 18 Suppl 5: v41-4

29. Kosch M, Levers A, Fobker M, Barenbrock M, Schaefer RM, Rahn KH, Hausberg M. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant. 2003, 18(7): 1370-5

30. Tarng DC, Huang TP, Wei YH, Liu TY, Chen HW, Wen Chen T, Yang WC. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis. 2000, 36(5): 934-44

31. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med. 1994, 17; 331(20): 1338-42

32. Schiffl H, Lang SM, Konig A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet. 1994, 27; 344(8922): 570-2

33. Jorres A, Gahl GM, Dobis C, Polenakovic MH, Cakalaroski K, Rutkowski B, Kisielnicka E, Krieter DH, Rumpf KW, Guenther C, Gaus W, Hoegel J. Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group. Lancet. 1999, 16; 354(9187): 1337-41

34. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000, 356(9223): 26-30

35. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med. 1999, 25(8): 814-2

36. Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J. 2004, 50(1): 102-9

37. Reiter K, D'Intini V, Bordoni V, Baldwin I, Bellomo R, Tetta C, Brendolan A, Ronco C. High-volume hemofiltration in sepsis. Theoretical basis and practical application. Nephron. 2002, 92(2): 251-8

38. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993 Apr; 21(4): 522-6

39. Maxvold NJ, Smoyer WE, Custer JR, Bunchman TE. Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Crit Care Med. 2000, 28(4): 1161-5

40. Jorres A. Extracorporeal treatment strategy in acute renal failure. Int J Artif Organs. 2002, 25(5): 391-6

41. Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant. 2001, 16 Suppl 5: 67-72

42. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999, 10(4): 846-53

43. Kolff WJ: New Ways of Treating Uremia. Churchill, London 1947

44. Tetta C, Mariano F. et al.: “Removal and generation of inflammatory mediators during continuous renal replacement therapies.”, in Bellomo, R. und Ronco, C. (Hrsg.): Critical Care Nephrology, Amsterdam 1998, S.1239-48

45. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002, 346(5): 305-10

46. van Bommel E, Bouvy ND, So KL, Zietse R, Vincent HH, Bruining HA, Weimar W. Acute dialytic support for the critically ill: intermittent hemodialysis versus continuous arteriovenous hemodiafiltration. Am J Nephrol. 1995, 15(3): 192-200

47. Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis. 1998, 32(2): 185-207

48. Schetz M. Classical and alternative indications for CRRT. Kidney Int. 1998, 53 (Suppl. 66): 129-32

49. Matuschak GM, Martinez LH. “Sepsis Syndrome: Pathogenesis, Pathophysiology and Management.” in Pinsky, MR.; Dhainaut, JF., (Hrsg.): Pathophysiologic foundations of critical care, New York 1993, S. 170-187

50. Schuster HP, Müller-Werdan U. Systematik der Therapie bei Sepsis und Multiorganversagen, in Schuster, HP., Werdan, K. (Hrsg.): Intensivtherapie bei Sepsis und Multiorganversagen, Berlin 1998, S. 87-104

51. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb; 115(2): 462-74

52. Lundberg JS, Perl TM, Wiblin T, Costigan MD, Dawson J, Nettleman MD, Wenzel RP. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med. 1998, 26(6): 1020-4

53. Young LS, Martin WJ, Meyer RD, Weinstein RJ, Anderson ET. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med. 1977, 86(4): 456-71

54. Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int. 1999, 56: 88-94

55. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003, 348: 138-50

56. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994, 15; 271(23): 1836-43

57. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993, 21(3): 318-27

58. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997, 25(7): 1115-24

59. Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T, Fischkoff S, Barchuk WT, Teoh L, Velagapudi R. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med. 2001, 27(7): 1169-78

60. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996, 334(26): 1697-702

61. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 1998, 351(9107): 929-33

62. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995, 273(12): 934-41

63. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993, 103(2): 565-75

64. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997, 349(9046): 170-3

65. van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis. 2001, 184(12): 1548-55

66. Jaber BL, Rao M, Guo D, Balakrishnan VS, Perianayagam MC, Freeman RB, Pereira BJ. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine. 2004, 25(5): 212-9

67. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med. 2003, 31(1): 34-8

68. Ma P, Chen D, Pan J, Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med. 2002, 30(5): 1046-50

69. Stuber F. Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? J Am Soc Nephrol. 2001, 12 Suppl 17: S60-4

70. Grootendorst AF, van Bommel EF, van Leengoed LA, van Zanten AR, Huipen HJ, Groeneveld AB. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care. 1993, 8(3): 161-9

71. Sieberth HG, Kierdorf HP. Is cytokine removal by continuous hemofiltration feasible? Kidney Int. 1999, 72: 79-83

72. Tetta C, Bellomo R, D'Intini V, De Nitti C, Inguaggiato P, Brendolan A, Ronco C. Do circulating cytokines really matter in sepsis? Kidney Int Suppl. 2003, (84): S69-71

73. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001, 27(6): 978-86

74. Kodama M, Hanasawa K, Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther Apher. 1997, 1(3): 224-7

75. Staubach KH, Rosenfeldt JA, Veit O, Bruch HP. Extracorporeal adsorption of endotoxin. Ther Apher. 1997, 1(1): 67-74

76. Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, Bisagni P, Giavaresi G, Bolzani R, Giardino R. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med. 2000, 28(5): 1526-33

77. Heering P, Grabensee B, Brause M. Cytokine removal in septic patients with continuous venovenous hemofiltration. Kidney Blood Press Res. 2003, 26(2): 128-34

78. Kellum JA, Dishart MK. Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats. Crit Care. 2002, 6(5): 429-33

79. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med. 1998, 26(12): 1995-2000

80. Levy H, Ash SR, Knab W, Steczko J, Carr DJ, Blake DE. Systemic inflammatory response syndrome treatment by powdered sorbent pheresis: the BioLogic-Detoxification Plasma Filtration System. ASAIO J. 1998, 44(5): M659-65

81. Silvester W. Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis. 1997, 30(5 Suppl 4): S38-43

82. Asanuma Y, Takahashi T, Koyama K, Kato T, Omokawa S, Sueoka A, Tanaka J. Exchange blood transfusion and on-line plasma exchange for sepsis in infants. ASAIO Trans. 1989, 35(3): 343-5

83. Stegmayr BG, Jakobson S, Rydvall A, Bjorsell-Ostling E. Plasma exchange in patients with acute renal failure in the course of multiorgan failure. Int J Artif Organs. 1995, 18: 45-52

84. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med. 1997, 23(8): 878-84

85. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome. Renal Failure. 1997, 19: 443-54

86. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003, 27(9): 792-801

87. Sanchez-Izquierdo JA, Perez Vela JL, Lozano Quintana MJ, Alted Lopez E, Ortuno de Solo B, Ambros Checa A. Cytokines clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis. 1997, 30(4): 483-8

88. Klouche K, Cavadore P, Portales P, Clot J, Canaud B, Beraud JJ. Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNFalpha and IL6 plasma concentrations. J Nephrol. 2002, 15(2): 150-7

89. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ.Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999 Oct; 27(10): 2096-104

90. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med. 1996, 22(12): 1360-7

91. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int. 1995, 48(5): 1563-70

92. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002, 30(1): 100-6

93. Grootendorst AF, van Bommel EF. The role of hemofiltration in the critically-ill intensive care unit patient: present and future. Blood Purif. 1993, 11(4): 209-23

94. Matamis D, Tsagourias M, Koletsos K, Riggos D, Mavromatidis K, Sombolos K, Bursztein S. Influence of continuous haemofiltration-related hypothermia on haemodynamic variables and gas exchange in septic patients. Intensive Care Med. 1994, 20(6): 431-6.

95. Gohl H, Buck R, Strathmann H. Basic features of the polyamide membranes. Contrib Nephrol. 1992; 96: 1-25

96. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med. 1995, 21(2): 169-76

97. Schetz M. Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med. 1994, 22(4): 715-6

98. Heering P, Grabensee B, Brause M. Cytokine removal in septic patients with continuous venovenous hemofiltration. Kidney Blood Press Res. 2003, 26(2): 128-34.

99. Hoffmann JN, Faist E. Removal of mediators by continuous hemofiltration in septic patients. World J Surg. 2001 May; 25(5): 651-9

100. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med. 1997, 23(8): 878-84

101. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol. 1995, 116: 62-75

102. Vanholder R, Van Haecke E, Veys N, Ringoir S. Endotoxin transfer through dialysis membranes: small- versus large-pore membranes. Nephrol Dial Transplant. 1992, 7: 333-9

103. Ronco C, Bonello M, Bordoni V, Ricci Z, D'Intini V, Bellomo R, Levin NW. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004, 22(1): 164-74

104. Ehrlich HJ, Bang NU. Protein C: „Physiologie, Biochemie und Molekularbiologie.“ In Müller-Berghaus, G. und Pötzsch, B. (Hrsg.): Hämostaseologie, 1998 Berlin, S. 327-40

105. Löffler G, Petrides EP. „Plasmaproteine“, in Löffler, G., Petrides, EP. (Hrsg.): Physiologische Chemie, Berlin 1988, S. 825

106. Mannick JA, Rodrick ML, Lederer JA. The immunologic response to injury. J Am Coll Surg. 2001, 193(3): 237-44

107. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004, 202(2): 145-56

108. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001, 29: S109–S116

109. Cohen J. The immunopathogenesis of sepsis. Nature. 2002, 420: 885–891

110. Moore FA, Moore EE. Evolving concepts in the pathogenesis of post injury multiple organ failure. Surg Clin North Am. 1995, 75: 257–277

111. Nagaki M, Hughes RD, Keane HM, Lau JY, Williams R. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock, 1992, 38: 182-8

112. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002, 30(6): 1250-5

113. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002, 30(10): 2205-11

114. Tsuchida K, Takemoto Y, Sugimura K, Yoshimura R, Nakatani T. Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. Int J Mol Med. 2002, 10(4): 485-8

115. Staubach KH, Boehme M, Zimmermann M, Otto V. A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber. Transfus Apheresis Sci. 2003, 29(1): 93-8

116. Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: the Japanese experience. Therap Apher Dial. 2003, 7(2): 252-8

117. Uriu K, Osajima A, Hiroshige K, Watanabe H, Aibara K, Inada Y, Segawa K, Anai H, Takagi I, Ito A, Kamochi M, Kaizu K. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis. 2002, 39(5): 937-47

118. Lee PA, Weger GW, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med. 1998, 26(4): 730-7

119. Honore PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level--the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004, 32(3): 896-7

120. Goldman M, Lagmiche M, Dhaene M, Amraoui Z, Thayse C, Vanherweghem JL. Adsorption of b 2-microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures. Int J Artif Organs. 1989, 12: 373-8

121. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992, 215(4): 356-62

122. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between Interleukin 6, Interleukin 1 and septic shock. J Exp Med. 1989, 169(1): 333-8

123. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, van Ingen J, vd Meer J, Hazenberg BP, Mulder PO, Weits J. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med. 1992, 20(2): 185-92

124. Barton BE. IL-6: Insights into novel biological activities. Clin Immunol Immunpathol. 1997, 85: 16-20

125. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991, 91(1): 23-9

126. Hamilton G, Hofbauer S, Hamilton B. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis. 1992, 24(3): 361-8

127. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med. 2002 May; 28(5): 651-5

128. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003, 16(3): 379-414

129. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med. 2001, 29(7 Suppl): S21-7

130. Kaslovsky RA, Lai L, Parker K, Malik AB. Mediation of endothelial injury following neutrophil adherence to extracellular matrix. Am J Physiol. 1993, 264(4 Pt 1): L401-405

131. Kaslovsky RA, Horgan MJ, Lum H, McCandless BK, Gilboa N, Wright SD, Malik AB.Pulmonary edema induced by phagocytosing neutrophils. Protective effect of monoclonal antibody against phagocyte CD18 integrin. Circ Res. 1990, 67(4): 795-802

132. Ayala A. Increased inducible apoptosis in CD4+ T-lymphocytes during polymicrobial sepsis. Immunology. 1999, 97: 45-55

133. Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, Siewert JR, Holzmann B. Selective defects of T-lymphocytes in patients with lethal intraabdominal infection. Am J Surg. 1999, 178: 288-92

134. Meldrum DR, Ayala A, Chaudry IH. Energetics of lymphocyte ‘burnout’ in late sepsis: adjuvant treatment with ATPMgC12 improves energetics and decreases lethality. J Surg Res. 1994, 56: 537–42

135. Toft P, Brix-Christensen V, Baech J, Krog J, Jorgensen HS, Tonnesen E, Petersen TK, Dagnaes-Hansen F. Effect of hemodiafiltration and sepsis on chemotaxis of granulocytes and the release of IL-8 and IL-10, Acta Anaesthesiol Scand. 2002, 46: 138-44

136. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML. Major injury leads to predominance of the T-helper type-2 lymphocyte phenotype and diminished IL-12 production associated with decreased resistance to infection. Ann Surg. 1995, 222: 482-90

137. Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001, 32(1): 76-102

138. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med, 1999, 25: 106-9

139. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL2/IFNgamma release while increasing IL-4/IL-10 production. J Surg Res. 1994, 56: 579-85

140. Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA. Surgical stress induces a shift in the type-1/type-2 helper cell balance, suggesting downregulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery. 1996. 119: 316-25

141. Ahmad S, Choudhry MA, Shankar R, Sayeed MM. Transforming growth factor-beta negatively modulates T-cell responses in sepsis. FEBS Lett. 1997, 402: 213-8

142. Grbic JT, Mannick JA, Gough DB, Rodrick ML. The role of prostaglandin E2 in immune suppression following injury. Ann Surg. 1991, 214: 253-62

143. Choudhry MA, Uddin S, Sayeed MM. Prostaglandin E2 modulation of p59fyn tyrosine kinase in T lymphocytes during sepsis. J Immunol. 1998, 160: 929-35

144. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993, 119(8): 771-78

145. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988, 318(23): 1481-86

146. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA; PICARD Study Group. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004, 65(4): 1357-65